Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 391

Sort by

Sort Order Select

Journal Articles

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton

Blood (2021) 138 (9): 785–789.

https://doi.org/10.1182/blood.2020010497

Published: 2021

Includes: Supplemental data

Journal Articles

The rise of a new “great teacher”

Amanda B. McBride, Pierluigi Porcu

Blood (2021) 138 (3): 205–206.

https://doi.org/10.1182/blood.2021011754

Published: 2021

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

Circulating angioimmunoblastic T-cell lymphoma cells

Konstantinos Liapis, Georgios Paterakis

Blood (2020) 135 (18): 1607.

https://doi.org/10.1182/blood.2020004944

Published: 2020

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Sangeetha Gandhi, MBBS, N. Nora Bennani, MD, Sonia Fortin, Thomas M. Habermann, MD, Patrick Johnston, MD, James R. Cerhan, MD PhD, Kay M. Ristow, BS, Carrie A. Thompson, MD, Grzegorz Nowakowski, MD, Yi Lin, MD PhD, Jose C Villasboas, MD, Luis Porrata, MD, Thomas E. Witzig, MD, Ivana Micallef, MD, David J Inwards, MD, Stephen M Ansell, MD PhD, Jonas Paludo, MD

Blood (2019) 134 (Supplement_1): 5293.

https://doi.org/10.1182/blood-2019-131965

Published: 2019

Journal Articles

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Nabin Karki, MBBS, Vamsi Kota, MBBS, Katherine Saunders, PharmD, Cara Iacobellis, PharmD, Anand Jillella, MD, Germame Ajebo, MD, Locke J. Bryan, MD

Blood (2019) 134 (Supplement_1): 5294.

https://doi.org/10.1182/blood-2019-129644

Published: 2019

Journal Articles

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Haiyan Yang, Tao Lei, Cong Li, Haifeng Yu, Zhongjian Chen

Blood (2019) 134 (Supplement_1): 5234.

https://doi.org/10.1182/blood-2019-129897

Published: 2019

Journal Articles

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Neetha Parameswaran, PhD, Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Lisa Durkin, Yvonne Parker, Daniel Lindner, MD PhD, Eric D. Hsi, MD, Deepa Jagadeesh, MDMPH

Blood (2019) 134 (Supplement_1): 1515.

https://doi.org/10.1182/blood-2019-131800

Published: 2019

Journal Articles

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Joshua C Pritchett, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Jose C Villasboas, MD, Andrew L. Feldman, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 1517.

https://doi.org/10.1182/blood-2019-131145

Published: 2019

Journal Articles

Role of Vav1 Genomic Alterations in T-Cell Differentiation and Transformation in Peripheral T-Cell Lymphoma

Jose Rodriguez Cortes, PhD, Anisha R. Cooke, Aidan Quinn, Ioan Filip, PhD, Juan Angel Patino, PhD, Raul Rabadan, PhD, Adolfo A. Ferrando, MD PhD, Teresa Palomero, PhD

Blood (2019) 134 (Supplement_1): 1482.

https://doi.org/10.1182/blood-2019-129438

Published: 2019

Journal Articles

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Swami P. Iyer, MD, Sattva S Neelapu, MD, Ethan Burns, MD, Ranjit Nair, MBBS,MD, Chitra Hosing, MD, Yago Nieto, MD PhD, Jason R. Westin, MD, Simrit Parmar, MBBS, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Madeleine Duvic, MD, Roberto N. Miranda, MD, Hun Ju Lee, Felipe Samaniego, MD, Sairah Ahmed, MD, Feng Lei, MS, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 1546.

https://doi.org/10.1182/blood-2019-132278

Published: 2019

Journal Articles

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Jing-Ping Zhang, PhD, Qi Gao, MLS, Alexander Chan, MD, Wenbin Xiao, MD PhD, Sary El Daker, PhD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 3978.

https://doi.org/10.1182/blood-2019-130406

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Daisuke Kaji, MD, Manabu Kusakabe, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Yasuhito Suehara, MD, Keiichiro Hattori, MD PhD, Yasunori Ota, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 4128.

https://doi.org/10.1182/blood-2019-127521

Published: 2019

Journal Articles

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Namrata S Chandhok, MD, Scott F. Huntington, MD MPH, Iris Isufi, MD, Lohith Gowda, MD MRCP, Mina L Xu, MD, Noffar Bar, MD, Stuart Seropian, MD, Francine M. Foss, MD

Blood (2019) 134 (Supplement_1): 4055.

https://doi.org/10.1182/blood-2019-128888

Published: 2019

Journal Articles

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Suchitra Sundaram, MD, Matthew Gravina, MD, Pallawi Torka, MD, Kristopher Attwood, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 4058.

https://doi.org/10.1182/blood-2019-132244

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

The rise of a new “great teacher”

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Circulating angioimmunoblastic T-cell lymphoma cells

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Potential Metabolites with Diagnostic Value in Plasma for Angioimmunoblastic T-Cell Lymphoma By LC-MS Based Untargeted Metabonomics Study

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Role of Vav1 Genomic Alterations in T-Cell Differentiation and Transformation in Peripheral T-Cell Lymphoma

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only